Induction of labour in an out patient setting?

(Extract from the Dr. Nalin Rodrigo Memorial Oration – June 2018)

M Goonewardene

Introduction

Induction of labour (IOL) is carried out in women with intact membranes as well as in women with pre labour rupture of membranes (PLROM), if continuing the pregnancy is considered dangerous to the fetus or to the mother or to both, and there is no contraindication for a vaginal delivery. There are well known absolute and relative contraindications for IOL, and IOL should not be carried out if it is considered dangerous to the mother, to the fetus or to both.

In 2010, through a large, worldwide, multicentre study involving nearly 300,000 women, the World Health Organisation estimated that globally, approx. 10% of pregnant women undergo IOL. The estimate was lowest from Niger (1.4%) and the highest was from Sri Lanka 35.5%)\(^1\). Globally, IOL rates are steadily increasing due to many reasons, and in fact it has been suggested that a vast majority of women in the world will have IOL in the future, not only if it is obstetrically indicated but perhaps even when it is most convenient to them and / or their obstetrician, rather than awaiting spontaneous onset of labour (SOL). It has been reported that IOL without medical indication at term (37-40 weeks of gestation) could be associated with reduced odds of caesarean delivery (CD) among nulliparous women as well as multiparous women with a previous vaginal delivery, and with no increase of adverse maternal or neonatal outcomes other than hyperbilirubinemia at early-term gestational ages\(^2\). Some obstetricians in North America have even recommend elective IOL for all women at 39 weeks’ gestation rather than at 41 weeks gestation\(^3,4\). However, opposition to this has arisen from advocates of natural pregnancy and birth\(^5,6\), especially because the recommendation is based primarily on a non increase of CD after IOL at 39 weeks’ gestation and a possible increase of still births after 39 weeks’ gestation\(^7\), without taking into consideration all the other possible harms of unnecessary IOL. Although the odds of perinatal mortality were seen to reduce with elective IOL at each gestation between 37 and 41 completed weeks when compared with expectant management, elective IOL was observed to be also associated with increased admission to a neonatal unit at all gestations before 41 weeks\(^7\). The American College of Obstetricians and Gynaecologists too have not recommended elective induction for non obstetric reasons\(^8\). In a recent large multi center study involving more than 3000 women, carried out in the USA, Induction of labour at 39 weeks in low-risk nulliparous women resulted in a significantly lower frequency of caesarean delivery (CD) although it did not result in a significantly lower frequency of a composite adverse perinatal outcome\(^9\).

\(^{1}\)Professor, Department of Obstetrics and Gynaecology,, International Medical University, Clinical Campus Seremban, Malaysia
Correspondence: MG, e-mail: <indramalikrodrigo@imu.edu.my >

http://orcid.org/0000-0002-7899-7117

Competing interest: The author reports no conflict of interest
In a population based study carried out in France in 2010, involving about 14,680 women, there were about 13.9% of elective IOL and 47.3% of them were on the request of the women10. Therefore it has been suggested that even in the UK, elective IOL at term on maternal request should be an option which should be available to women11, although the NICE Guidelines do not recommend this12. It is widely accepted that women should be involved in their care and that this includes decisions regarding IOL1,12-16. It has been reported that a significant number of women who undergo IOL, as an inpatient in a hospital, may feel that they did not have adequate time and information to make an informed decision and actively participate in their IOL13. Some women prefer to have greater involvement and control over their management processes in a comfortable and supportive home environment. However, women who reside a significant distance away from their hospital may feel ‘safer’ in hospital and their preferences may vary according to the services available to them as well as their socio-demographic backgrounds12,14-16.

Methods of Induction of labour

It is reported that IOL was first described by the ‘Father of Medicine’ himself (Hippocrates, circa 400 BC). What he described was mammary stimulation and mechanical dilation of the cervical canal. This was followed by artificial rupture of membranes (amniotomy), which was practiced by Soranus (circa AD 103)17. In 1909, Bell described the use of an extract from the pituitary for IOL18, but it had serious side effects including rupture of the uterus. After Vincent du Vigneaud et al synthesized oxytocin in 195419, the intra venous infusion of synthetic oxytocin, mostly in combination with amniotomy, became the preferred method for IOL. Embrey and Mollison in 1967 described the supra cervical placement of a Foley catheter for ripening of the cervix to make it favourable for IOL20 while Karim et al introduced the use of prostaglandins for IOL in 196821.

Currently, a low dose of oral misoprostol (OM), a synthetic methyl analogue of prostaglandin E10, has come to the fore front as a method for IOL22-25, and there is also a concerted effort to identify the most convenient and cost effective method of cervical ripening and IOL, which could be safely adopted even in an outpatient setting14,16,27-32. Since there is no clear demarcation between ripening of the cervix and SOL and because the former merges in to the latter in one continuous process, in clinical practice, most interventions used to ripen the cervix prior to IOL will lead to IOL with stimulation of uterine muscle contractions, if used in increasing doses and frequency and for longer durations. This is exemplified by the insertion of a supra cervical Foley catheter. As it does not need intensive maternal or fetal monitoring, and has been shown to be safe and effective for IOL if kept in situ for four days, according to the currently available evidence, a supra cervical Foley catheter could be considered as an appropriate method for outpatient IOL24,26,28-30,31,32. It has also been shown that IOL with the use of a supra cervical Foley catheter as an outpatient procedure is cost effective22. There is also an increased interest on the feasibility of telemonitoring of women in their homes itself, during pregnancy and labour33-35. Therefore outpatient IOL with low dose OM and telemonitoring of the mother and fetus may become a reality in the future.

Low dose oral misoprostol

Compared to vaginal misoprostol, low dose OM has been shown to be safer, with less risks of hyperstimulation, CD, delivery of babies with Apgar <7, and post partum haemorrhage, and also to be more effective than amniotomy with intravenous oxytocin, which can result in increased CD, especially if the cervix is ‘not ripe’22-25. Regimens of 20-200 µg of OM given four to six hourly, and up to 12 doses of 50 µg over four days have been reported22-26. A starting dose of 20 µg of OM in solution, titrated against uterine contractions and administered hourly in increasing doses of up to 60 µg, is currently thought to be a safe, cost effective method for IOL22-25, although more simplified regimens are needed56. The hourly dosing regimen has been calculated according to the pharmokinetics of OM where its half-life as well as the time taken to achieve peak serum concentrations has been estimated to vary from approximately 20-40 mins respectively25,27. Although doses of 20, 40 and 60 µg of OM are easily prepared by dissolving the commonly available 200 µg tablet in 200 ml of water, 25 µg tablets are also now available, and a more practical regimen of 50 µg administered four hourly, could be implemented22,26,43,44. This would be useful in settings with a heavy work load and lacking facilities for one to one nursing care and intensive fetal monitoring. The induction delivery interval (IDI) possibly being slightly longer after low dose OM should not be considered as a major draw-back. The fact that it is safer than vaginal misoprostol, results in less CD and is also effective with an ‘unripe’ cervix in contrast to amniotomy and intra venous infusions, indicate that it should be the preferred method for IOL now, unless a better method is found in the future22-23. The increased occurrence of

Sri Lanka Journal of Obstetrics and Gynaecology
meconium stained liquor, without any associated evidence of neonatal asphyxia (risk of Appgar <7 is reduced with OM) suggests that the passage of meconium could be due to stimulation of the fetal gut by OM23. However, the maternal and fetal well-being need to be closely monitored when administering low dose OM. There are several advantages of low dose OM. These include: being more acceptable to women compared to vaginal or intravenous interventions, being easier to be administered, can be stored at room temperature (unlike vaginal dinoprostone), being cheaper and cost effective compared to vaginal dinoprostone, and being associated with lower CD rates.

Supra cervical Foley catheter

Although less effective than OM and vaginal misoprostol, vaginal dinoprostone, and amniotomy with oxytocin infusion, the placement of a supra cervical Foley catheter has the advantage of having the least risk of hyper stimulation22,24. The use of a larger volume of fluid (eg 60-80 ml) in the bulb of the Foley catheter has been shown to be associated with increased vaginal delivery in 24 hours (VD 24), although no significant differences in CD rates have been observed18. Although the supra cervical Foley catheter is often removed after 24 hours due to concerns of possible ascending infections, there does not appear to be a significant increase of adverse effects including chorioamnionitis associated with the insertion of a supra cervical Foley catheter for IOL24,31,39,40. Keeping the Foley catheter up to three days and four days has been shown to be safe and effective for IOL in Africa41 and the Netherlands26 respectively. A recent Systematic Review has shown that the risk of adverse effects during the period between insertion and expulsion of a supra cervical balloon catheter used for outpatient cervical ripening is low31. Furthermore it has been shown that outpatient cervical ripening with a supra cervical Foley catheter could potentially save almost € 1000/= per woman32. However, the Foley catheter should not be inserted in the presence of overt vaginal or cervical infection, and appropriate antiseptic measures and sterile procedures should be adopted during its insertion. The urinary channel of the Foley catheter should be closed off with a sterile cap and the catheter should be taped to the woman’s thigh, applying gentle traction.

The advantages of a supra cervical Foley catheter include: being a possible alternative for women who wish to have IOL at home, can be stored at room temperature (unlike vaginal dinoprostone), being cheaper than vaginal dinoprostone, having the least risk of uterine hyper stimulation and fetal heart rate changes, requiring less stringent need for maternal and fetal monitoring, requiring no further intervention until the Foley catheter falls out, being more suitable with a scarred uterus, being more suitable in women at risk of fetal compromise (eg Pre eclampsia & Fetal Growth Restriction), and having no evidence of increased risk of adverse events (eg. Chorioamnionitis).

Research on Oral Misoprostol versus the insertion of a supra cervical Foley catheter for ripening the cervix and induction of labour, carried out in a Teaching Hospital in Sri Lanka

Three RCTs have been carried out. Ethical approval for these studies was obtained from the Ethical Review Committee of the Faculty of Medicine, University of Ruhuna. Administrative approval was obtained from the Directors of the THMG during the periods of study. The RCTs were registered in the Sri Lanka Clinical Trials Register. Informed written consent was obtained from all the participants in all the RCT. In all three RCT, although the patients could not be blinded to the interventions, the investigators and the analysts of the results were blinded with regard to the intervention. Similar methods were used in all three RCT42-43.

1) The first RCT was carried out in 2010/2011. The objective was to compare the effectiveness of the insertion of a supra cervical Foley catheter for 24 hrs versus two doses of OM 25 g four hours apart, in pre IOL cervical ripening, in postdated pregnancies. There were 156 consecutive women with uncomplicated singleton pregnancies having a vertex presentation and MBS < 6 at 40 weeks + 6 days of gestation, who were allocated by stratified (primip/multip) block randomization in a 1:1 ratio to receive either two doses of OM 25 µg, four hours apart (n=74) or a supra cervical Foley Catheter for 24 hrs (n=78). The MBS before and after the intervention was assessed in all participants by an investigator who was adequately trained and skilled in this procedure, and blind to the intervention. If the cervix was favourable, IOL was carried out with amniotomy and intravenous oxytocin infusion.

Results: There were no significant differences in the distribution of parity, and the mean ages and the mean pre intervention MBS in the primigravidae and multigravidae, between the two study groups. There were no drop outs. There were significant
increases in mean MBS (ranging from 2.6-3.3 and 95% CI 1.7-4.1, p<0.001) after the inter-ventions in both groups. However there was no significant difference between the mean increases of MBS between the groups. In the primigravidae, the mean MBS after 24 hours was greater in the Foley catheter group compared to the OM group (6.9, 95% CI 6.3-7.5 vs 5.7, 95% CI 4.8-6.7, p<0.05).

There were no significant differences in the proportions of primips and multips had cervices not in labour after 48 hours (30% vs. 9%; RR=3.3, 95% CI 1.8-4.8, p<0.001), and inferior to a supra cervical Foley catheter for pre-induction cervical ripening in post dated pregnancies.

Conclusions: Insertion of a supra cervical Foley catheter for 24 hours was better than two doses of 25 g OM administered four hours apart, for pre IOL cervical ripening in post dated pregnancies.

2) The second RCT was carried out in 2015/2016. The objective was to compare three doses of OM 50 µg four hourly versus a supra cervical Foley catheter for 24 hours, for pre-induction cervical ripening. This study involved 180 women who were allocated to receive three doses of OM 50 µg four hourly (n=91) or a supra cervical Foley catheter for 24 hours (n=89). MBS was reassessed at 41 weeks gestation. If MBS was >7, IOL was carried out with amniotomy and intravenous oxytocin infusion. If MBS was <7, cross over therapy was carried out with a supra cervical Foley catheter for OM group and vaginal prostaglandin E2 for the Foley catheter group.

Results: At commencement, there were no significant differences in age, parity, body mass index and MBS between the two groups. There were no drop outs. Greater proportions established labour in both primigravidae (30% vs. 9%; Relative Risk (RR) =4.4, 95% CI 1.3-14.6; p=0.01) and multigravidae (44% vs.16%; RR=4.3; 95% CI 1.6-11.8; p=0.003) before 41 weeks’ gestation in OM group compared to the Foley catheter group. Among the multigravidae, the mean increase of MBS was greater in the OM group (3.1; 95% CI 2.4-4) compared to the Foley group (2.4; 95% CI 1.9-2.7, p=0.04). One primigravida and two multigravidae developed hyper stimulation after OM. No significant differences were seen in the other maternal and perinatal outcomes.

Conclusions: Compared to a supra cervical Foley catheter for 24 hours, three doses of OM 50 µg four hourly was more effective for cervical ripening and even resulted in IOL.

3) The third RCT was carried out in 2016 / 2017. The objective was to compare the effectiveness of IOL with three doses OM 50 µg four hourly per day for 48 hours versus a supra cervical Foley catheter for 48 hours in women at 40 weeks + 5 days gestation. There were 144 women having MBS 5 at 40 weeks + 5 days gestation who were allocated to receive three doses of OM 50 µg given four hourly per day for 48 hours (n=72) or a supra cervical Foley catheter for 48 hours (n=72).

Results: At commencement, there were no significant differences in age, parity, body mass index and MBS between the two groups. There were no drop outs. Compared to a supra cervical Foley catheter, with OM, successful IOL was higher (RR 1.4, 95% CI 1.1-1.9, p=0.029), mean increase in MBS in those not in labour after 48 hours was greater (4.8, 95% CI 4.1-5.4 vs 4.1 95% CI 3.8-4.4, p=0.017), VD 24 was more (RR 4.2, 95% CI 1.8-9.6, p<0.001), IDI were shorter, more hyperstimulation and meconium stained liquor were seen, but no significant difference were seen in CD rates.

Conclusion: Three doses of OM 50 µg given four hourly per day for 48 hours was more effective than a supra cervical Foley catheter for 48 hours, for IOL.

Therefore in summary we concluded that: two doses of 25 g OM administered four hours apart, was inadequate and inferior to a supra cervical Foley catheter for pre induction cervical ripening in post dated pregnancies compared to a supra cervical Foley catheter for 24 hours, three doses of OM 50 g four hourly was more effective for cervical ripening and even resulted in IOL, and three doses of OM 50 µg given four hourly per day for 48 hours was feasible and more effective than a supra cervical Foley catheter for 48 hours, for IOL.

Conclusions
As OM has been shown to be feasible and effective for IOL, it should be considered as an option for IOL.
in Sri Lanka. As the trans cervical insertion of a supra cervical Foley catheter which could be kept in situ for 48 hours has been shown to be equally effective as OM for IOL, for low risk women staying close to their hospitals and preferring outpatient IOL, the insertion of a supra cervical Foley catheter appears to be a suitable option, while adopting suitable measures for the prevention / early detection and treatment of possible complications, which however have been shown to be minimal. When considering the current best available evidence, the common practice in several obstetric units in Sri Lanka, of removing the supra cervical Foley catheter after 24 hours, should be discouraged. In the Cochrane Review which included 34 studies with 5003 women, outpatient IOL was found to be feasible and effective, with a reduction in the need for interventions as well as shortened IDIs, and adverse events appeared to be rare5. Further research is needed to identify the safest, cost effective outpatient method of IOL which is preferred by women. In view of the availability of prostaglandins the MBS should be used only as a score to decide the modality of IOL and not to assess the favourability of the woman for IOL. In view of recent evidence, vaginal delivery in 24 hrs (VD24) should not be a criterion to assess “successful IOL” and CD for a “failed IOL” could be delayed up to four days, in the absence of any maternal or fetal complications. In the future, outpatient IOL with low dose OM and telemonitoring of the mother and fetus may become a reality.

References
1. World Health Organization. WHO Recommendations for induction of labour 2011. WQ440, World Health Organization, Geneva, Switzerland.
2. Darney BG, Snowden JM, Cheng YW et al. Elective Induction of Labor at Term Compared With Expectant Management. Maternal and Neonatal Outcomes. Obstet Gynecol. 2013 Oct; 122(4): 761-769.
3. Lockwood C, Norwitz E. To induce or not to Induce: the colloquia session 39 weeks debate (pt1) ACOG Annual Clinical Meeting, Jun 8, 2016. Available at:www.howardisms.com/obgyn/to-induce-or-not-to-induce-the-39-weeks-debate-part-1/ [Accessed 02.02.2018].
4. Lila O’ Connor, Ed. Elective induction of labor at 39 (vs 41) weeks: Caveats and considerations. OBG Manag. 2016 May; 28(5) [Accessed 02.02.2018]
5. Modern alternative pregnancy. Mandatory induction at 39 weeks: ACOG has gone too far. Available at: www.modernalternativepregnancy.com/.../mandatory-induction-39-weeks-acog-gone-far/ [Accessed 02.02.2018].
6. Pip Wynn Owen. Mandatory induction at 39 weeks: No, No, No! What happened to “first do no harm”? www.birthsavvy.com.au/induction-at-39-weeks/ [Accessed 02.02.2018].
7. Stock SJ, Ferguson E, Duffy A, Ford I, Chalmers J, Norman JE. Outcomes of elective induction of labour compared with expectant management: population based study. BMJ. 2012 May 10; 344: e2838. doi: 10.1136/bmj.e2838. [Accessed 02.02.2018].
8. ACOG Committee on Practice Bulletins – Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol. 2009; 114 (2 Part 1): 386-397, Reaffirmed in 2016.
9. Grobman WA, Rice MM, Reddy UM, Tita ATN, Silver RM, Mallett, G et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med 2018; 379: 513-23. DOI: 10.1056/NEJMoa1800566
10. Coulm B, Blondel B, Alexander S, Boulvain M, Le Raya C. Elective induction of labour and maternal request: a national population-based study. BJOG 2016; 123: 2191-2197.
11. Norman JE, Stock SJ. Elective induction of labour on maternal request: why do we continue to deny women this option? BJOG 2016; 123: 2198.
12. National Institute of Clinical Excellence, Induction of labour (2008) NICE guideline CG170- 8-year surveillance 2017. Available at: https://www.nice.org.uk/guidance/cg70/chapter/guidance#information-and-decision-making. and https://www.nice.org.uk/guidance/qs60. [Accessed 02.02.2018].
13. Moore JE. Moving Towards Patient Centered Care: Women’s Decisions, Perceptions, and Experience of the Induction of Labor Process. A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Nursing). The University of Michigan 2012. [Accessed 02.02.2018].
14. Oster C, Adelson PL, Wilkinson C, Turnbull D. Inpatient versus outpatient cervical priming for induction of labour: Therapeutic landscapes and women’s preferences. Health & Place 2011; 17: 379-385.
15. Reid M, Lorimer K, Norman JE, Bollapragada SS, Norrie J. The home as an appropriate setting for women undertaking cervical ripening before the induction of labour. Midwifery 2011; 27: 30-35.

16. Howard K, Gerard K, Adelson P, Bryce R, Wilkinson C, Turnbull D. Women’s preferences for inpatient and outpatient priming for labour induction: a discrete choice experiment. BMC Health Services Research 2014, 14: 330-341.

17. Sanchez-Ramos, L, Kaunitz, A. Induction of Labor in: Glob. Libr. Women’s Med., (ISSN: 1756-2228) 2009; DOI 10.3843/GLOWM.10130. [Accessed 02.02.2018].

18. Bell WB. The pituitary body. BMJ 1909; 2: 1609-13.

19. Vincent du Vigneaud, Charlotte Ressler, John M. Swan, Carleton W. Roberts, Panayotis G. Katsyoyannis. The Synthesis of Oxytocin. J. Am. Chem. Soc., 1954, 76 (12): 3115-3121DOI: 10.1021/ja01641a004. [Accessed 02.02.2018].

20. Embrey MP, Mollison BG. The unfavourable cervix and induction of labour using a cervical balloon. J Obstet Gynaecol Br Commonw 1967; 74(1): 44-8.

21. Karim SMM, Trussele RR, Patel RC, Hillier K. Response of pregnant human uterus to prostaglandin F2 alpha induction of labour. BMJ 1968; 4: 621-3.

22. Alfirevic Z, Keeney E, Dowswell T, et al. Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis. BJOG.2016; 123: 1462-70.

23. Alfirevic Z, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev2014. Issue 6. Art. No.: CD001338. DOI: 10.1002/14651858.CD001338.pub3. [Accessed 02.02.2018].

24. Chen W, Xue J, Peprah MK, et al. A systematic review and network meta-analysis comparing the use of Foley catheters, misoprostol and dinoprostone for cervical ripening in the induction of labour. BJOG 2016; 123: 346-354.

25. Cheng S-Y, Ho Ming H, Lee JC. Titrated Oral Compared With Vaginal Misoprostol for Labor Induction A Randomized Controlled Trial. Obstet Gynecol 2008; 111: 119-25.

26. ten Eikelder MLG, Katrien Oude Rengerink et al. Induction of labour at term with oral misoprostol versus a Foleycatheter (PROBAAT-II): a multi-center randomized controlled non-inferiority trial. The Lancet 2016; 387: 1619-1628.

27. Dowswell T, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Different methods for the induction of labour in outpatient settings. Cochrane Database Syst Rev 2010, Issue 8. Art. No.: CD007701. DOI: 10.1002/14651858.CD007701.pub2. [Accessed 02.02.2018].

28. Kelly AJ, Alfirevic Z, Ghosh A. Outpatient versus inpatient induction of labour for improving birth outcomes. Cochrane Database Syst Rev 2013, Issue 11. Art. No.: CD007372. DOI: 10.1002/14651858.CD007372.pub3.

29. Henry A, Madan A, Rachel Reid R, et al. Outpatient Foley catheter versus inpatient prostaglandin E2 gel for induction of labour: a randomised trial. BMC Pregnancy Childbirth 2013, 13:25 :36 http://www.biomedcentral.com/1471-2393/13/25.

30. Adelson PL, Wedlock GR, Wilkinson CS, Howard K, Bryce RL, Turnbull DA. A cost analysis of inpatient compared with outpatient prostaglandin E2 cervical priming for induction of labour: results from the OPRA trial. Australian Health Review 2013; 37: 467-473.http://dx.doi.org/10.1071/ AH13081. [Accessed 02.02.2018].

31. Diederen, M, JSM Gommers JSM, Wilkinson C, Turnbull D, Mol BWJ. Safety of the balloon catheter for cervical ripening in outpatient care: complications during the period from insertion to expulsion of a balloon catheter in the process of labour induction: a systematic review. BJOG 2018: https://doi.org/1471-0528.15047. [Accessed 02.02.2018].

32. ten Eikelder MLG, van Baaren G-I, Rengerink KO et al. Comparing induction of labour with oral misoprostol or Foley catheter at term: cost-effectiveness analysis of a randomized controlled multi-centre non-inferiority trial. BJOG 2018; 125: 375-383.

33. Alessia Dessi, Danilo Pani, Luigi Raffo. An advanced algorithm for fetal heart rate estimation from non-invasive low electrode density recordings. Physiological Measurement 2014; 35 (Num. 8), doi:10.1088/0967-3343/35/8/1621, 28 July 2014. [Accessed 02.02.2018].

34. Abdullah Bin Queyam, Sharvan Kumar Pahuja and Dilbag Singh. Non-invasive feto-maternal well-being monitoring: a review of methods. J Engin Sc Technol Rev 2017; 10 (1): 177-190.
35. Seale D, Buysse H, Park JB, de la Torre I. Effectiveness of telemonitoring in obstetrics: Scoping Review. J Med Internet Res. 2017 Sep; 19(9): e327. doi: 10.2196/jmir.7266. [Accessed 02.02.2018].

36. Weeks AD, Navaratnam K, Alfirevic Z. Simplifying oral misoprostol protocols for the induction of labour. BJOG 2017; https://doi.org/10.1111/1471-0528.14657. [Accessed 02.02.2018].

37. Abdel-Aleem H, Villar J, Gulmezoglu AM, et al. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Euro J Obstet Gynecol Reprod Biol 2003;108(1): 25-8.

38. Berndl A, El-Chaar D, MurphyK, Mc Donald S. Does cervical ripening at term using a high volume foley catheter result in a lower caesarean section rate than a low volume foley catheter? A Systematic Review and Meta-Analysis. J Obstet Gynecol Can 2014; 36: 678-687.

39. Jozwiak M, Bloemenkamp WMK, Kelly AJ, Mol WB, Irion O, Boulvain M. Mechanical methods for induction of labour. Cochrane Database of Syst Rev 2012, Issue 3. Art. No.: CD001233. DOI: 10.1002/14651858.CD001233.pub2. [Accessed 02.02.2018].

40. Leopold B, Sciscione A. Is there a place for outpatient preinduction cervical ripening? Obstet Gynecol Clin N Am 2017; 44: 583-591.

41. Ekele BA, Isah AY. Cervical ripening: how long can the Foley catheter safely remain in the cervical canal? African J of Reprod Health 2002; 6 (3): 98-102.

42. Goonewardene M, Kumara DMA, Ziard MH, Bhabu B. Intra Cervical Foley Catheter vs Oral Misoprostol for Pre Induction Cervical Ripening of Postdated Pregnancies. Sri Lanka J Obstet Gynaecol 2014; 36 (3): 66-70.

43. Somirathna D, Goonewardene M. Intra cervical Foley catheter for 24 hours vs three doses of oral Misoprostol for pre-induction cervical ripening in post dated pregnancies: a randomized controlled trial. Ceylon Med J 2017; 62 (2) 77-82.

44. Amarasena BA, Goonewardene IMR, Perera RN, Rameez MFM. Oral misoprostol for 48 hours versus an intra cervical Foley catheter for 48 hours for induction of labour in post dated pregnancies: a randomized control study. Abstracts of the 50th Scientific Session of the Sri Lanka College of Obstetrics & Gynaecology, Sri Lanka J Obstet Gynaecol 2017; EO 027, p 10-1

45. Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database of Syst Rev. 2017, CD 0 0 7 7 0 1 . h t t p s : / / d o i . o r g / 1 0 . 1 0 0 2 / 1 4 6 5 1 8 5 8 . C D 0 0 7 7 0 1 . p u b 3 [Accessed 02.02.2018].